Page 158 - 南京医科大学自然版
P. 158
第44卷第12期
·1772 · 南 京 医 科 大 学 学 报 2024年12月
mune globulin to high⁃risk infants and young children［J］. flops again in lung cancer［EB/OL］.（2021⁃07⁃28）［2024⁃
N Engl J Med，1993，329（21）：1524-1530 04 ⁃ 28］. https：//www. fiercebiotech. com/ biotech/gsk ⁃
［66］JO W K，SCHADENHOFER A，HABIERSKI A，et al. Re⁃ drops⁃phase⁃2⁃viral⁃vector⁃rsv⁃vaccine⁃pediatric⁃ages
verse genetics systems for contemporary isolates of respi⁃ ［74］BERGERON H C，TRIPP R A. Breakthrough therapy des⁃
ratory syncytial virus enable rapid evaluation of antibody ignation of nirsevimab for the prevention of lower respira⁃
escape mutants［J］. Proc Natl Acad Sci U S A，2021，118 tory tract illness caused by respiratory syncytial virus in⁃
（14）：e2026558118 fections（RSV）［J］. Expert Opin Investig Drugs，2022，31
［67］STIBOY E，CHAN M，ISLAM M S，et al. Variation in clin⁃ （1）：23-29
ical practice guidelines for use of palivizumab in prevent⁃ ［75］GRIFFIN M P，YUAN Y，TAKAS T，et al. Single⁃dose nir⁃
ing severe respiratory syncytial viral（RSV）disease in high sevimab for prevention of RSV in preterm infants［J］. N
⁃risk infants［J］. Pediatr Pulmonol，2023，58（4）：1210- Engl J Med，2020，383（5）：415-425
1220 ［76］Nirsevimab shows positive topline results in RSV phase 2/
［68］JARTTI T，BØNNELYKKE K，ELENIUS V，et al. Role of 3 MEDLEY trial［EB/OL］.（2021⁃06⁃28）［2024⁃05⁃10］.
viruses in asthma［J］. Semin Immunopathol，2020，42 https：//www. sanofi. com/en/media ⁃ room/press ⁃ releases/
（1）：61-74 2021/2021⁃06⁃28⁃08⁃00⁃00⁃2253567
［69］CHATTERJEE A，MAVUNDA K，KRILOV L R. Current ［77］TANG A M，CHEN Z F，COX K S，et al. A potent broadly
state of respiratory syncytial virus disease and manage⁃ neutralizing human RSV antibody targets conserved site
ment［J］. Infect Dis Ther，2021，10（Suppl 1）：5-16 Ⅳ of the fusion glycoprotein［J］. Nat Commun，2019，10
［70］FROGEL M P，STEWART D L，HOOPES M，et al. A sys⁃ （1）：4153
tematic review of compliance with palivizumab adminis⁃ ［78］Efficacy and safety of MK⁃1654 in infants（MK⁃1654⁃004）
tration for RSV immunoprophylaxis［J］. J Manag Care ［EB/OL］.（2022⁃12⁃12）［2023⁃05⁃17］. https：//clinicaltri⁃
Pharm，2010，16（1）：46-58 als. gov/ct2/show/NCT04767373?term=MK1654&c ⁃ ond=
［71］ALANSARI K，TOAIMAH F H，ALMATAR D H，et al. RSV&draw=2&rank=3
Monoclonal antibody treatment of RSV bronchiolitis in ［79］CUNNINGHAM S，PIEDRA P A，MARTINON⁃TORRES
young infants：a randomized trial［J］. Pediatrics，2019， F，et al. Nebulised ALX⁃0171 for respiratory syncytial vi⁃
143（3）：e20182308 rus lower respiratory tract infection in hospitalised chil⁃
［72］SUN M Y，LAI H H，NA F Y，et al. Monoclonal antibody dren：a double ⁃ blind，randomised，placebo ⁃ controlled，
for the prevention of respiratory syncytial virus in infants phase 2b trial［J］. Lancet Respir Med，2021，9（1）：21-
and children：a systematic review and network meta⁃analy⁃ 32
sis［J］. JAMA Netw Open，2023，6（2）：e230023 ［收稿日期］ 2024-04-18
［73］ GSK culls phase 2 RSV vaccine in kids，as Feladilimab （本文编辑：陈汐敏）
